Publication number: 20230108594
Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
Type:
Application
Filed:
January 28, 2022
Publication date:
April 6, 2023
Inventors:
Samuel SPERRY, Alan X. XIANG, Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Mike SHAGHAFI, Theo Michels, Christian NILEWSKI, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan GRUBBS, Kaveri URKALAN, Takasuke MUKAIYAMA
Patent number: 11286268
Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
Type:
Grant
Filed:
June 30, 2020
Date of Patent:
March 29, 2022
Assignee:
eFFECTOR Therapeutics, Inc.
Inventors:
Samuel Sperry, Alan X. Xiang, Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Mike Shaghafi, Theo Michels, Christian Nilewski, Chinh Viet Tran, Garrick Kenneth Packard, Alan Grubbs, Kaveri Urkalan, Takasuke Mukaiyama
